Life-changing therapies

Pipeline
Collaborations
About us
Join our team

Latest news

• Polyphor announces progress of the Phase III immuno-oncology program with balixafortide. Renewed strategy in advancing antibiotics and oncology research and pipeline

• Polyphor appoints Gökhan Batur as Chief Executive Officer

See all news

Meet us at

January 16, 2020	Octavian Seminar Hotel Mariott | Zurich | Switzerland
January 13 – 16, 2020	J.P. Morgan 38th Annual Healthcare Conference San Francisco | CA |  USA

 

Event calendar

Pipeline

Immuno-Oncology

Balixafortide (POL6326)
CXCR4 Inhibitor; metastatic breast cancer in combination with eribulin

Fast Track Designation granted by FDA

Phase III

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Balixafortide (POL6326)
CXCR4 Inhibitor; other conditions/indications

Preclinical

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Cystic Fibrosis / Respiratory

Inhaled Murepavadin – Pseudomonas infections in CF

Preclinical

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Antibiotics

OMPTA platform –  targeting Gram-negative resistant pathogens

Lead preclinical compound: POL7306

 

Preclinical

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Other

Cystic Fibrosis

POL6014 –Inhaled Elastase Inhibitor

Outlicensed to Santhera Pharmaceuticals 14.02.2018

Phase I

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Macrocycle discovery platform

New modalities to address challenging biological targets

Learn more